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Impact statement 
The epidemiology of vulvar cancer (VSCC) is changing. Our data reveal that 
the age at which women are diagnosed with VSCC is falling. High-risk (HR) 
human papillomavirus (HPV) infection is very common in vulvar intraepithelial 
neoplasia (VIN) and present in just over 50% of VSCC. HR-HPV positivity was 
associated with lower progression rates from VIN to VSCC and improved 
progression-free survival of VSCC. 
 
Short Title: HPV positivity correlates with improved outcome in invasive 
vulvar cancer. 
 
Submitted to: Infectious Causes of Cancers 
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Abbreviations: 
HPV, human papillomavirus 
HR-HPV, high risk- human papillomavirus  
VSCC, Vulvar squamous cell cancer 
VIN, Vulvar intraepithelial neoplasia,  
CIN, cervical intraepithelial neoplasia 
OPSCC, oropharyngeal squamous cell cancer  
LSIL low grade squamous intraepithelial lesion 
HSIL high grade squamous intraepithelial lesion 
(FFPE), formalin fixed, paraffin-embedded 
NOS, not otherwise specified 
NA, nucleic acid 
SIMD, Scottish Index of Multiple Deprivation  
OS, overall survival  
PFS, progression free survival  
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Abstract  
 
It is universally accepted that high-risk human papillomavirus (HR-HPV) is the 
cause of cervical dysplasia and cancer. More recently it has been shown that 
HPV is also a marker of clinical outcome in oropharyngeal cancer. However, 
contemporary information is lacking on both the prevalence of HPV infection 
in vulvar cancer (VSCC), its precursor lesion, vulvar intraepithelial neoplasia 
(VIN) and the influence of HPV-status on the prognosis of this malignancy. 
We have conducted a detailed population-based study to examine rates of 
progression of VIN to VSCC, type-specific HPV prevalence in vulvar disease 
and the influence of HPV status on clinical outcome in VSCC. We observed 
that the age at which women are diagnosed with VSCC is falling and there is 
a significant time gap between first diagnosis of VIN and progression to 
invasive disease. HR-HPV infection was detected in 87% (97/112) cases of 
VIN and 52% cases (32/62) of VSCC. The presence of HR-HPV in squamous 
intraepithelial lesion was associated with lower rates of progression to 
invasive cancer (hazard ratio, 0.22, p=0.001).   In the adjusted analysis, HR-
HPV was associated with improved progression-free survival of VSCC 
compared to those with HPV negative tumours (hazard ratio, 0.32, p=0.02). 
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Introduction 
 
Squamous cell cancer of the vulva accounts for about 3-4% of genital cancers 
among women with an estimated 30,000 new cases diagnosed per year 
worldwide. 1 There is evidence that vulvar squamous cell cancer (VSCC) and 
its precursor lesion, vulvar intraepithelial neoplasia (VIN) is increasing. 
Recently, we reported that the incidence of vulvar cancer in Scotland has 
increased by about 64% in the past three decades, particular among young 
women. 2, 3  The reasons behind the changing epidemiology of vulval disease 
are unclear but it may be driven by a secular increase in HPV infection and/or 
changed behaviors that have facilitated the transmission. 
 
The estimates of HPV prevalence in VIN reported in an international meta-
analysis were 84%.4 VIN is challenging to manage - surgical or topical 
treatment can be associated with significant morbidities. Natural history 
studies indicate that around 10% of VIN will progress to cancer although 
comprehensive, global data are relatively sparse when compared to other 
HPV-associated neoplasms.5 For cervical intraepithelial neoplasia (CIN) the 
estimated spontaneous regression rate is between 30 and 50%, with about 10 
to 40% progressing to invasive cancer if untreated.6 Factors that predict 
progression of VIN to invasive disease are poorly characterised. 
 
HPV status is considered a marker of favorable clinical outcome in 
oropharyngeal squamous cell cancer (OPSCC) compared to HPV-negative 
tumours.7 As nearly all cervical cancers are positive for HPV, few studies 
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have looked at HPV status and clinical outcome, although there is some 
evidence to suggest that cancers where HPV is not detectable have a worse 
prognosis.8 Although the global data on HPV type-specific epidemiology in 
VSCC are less comprehensive compared to cervical cancer and OPSCC, 
current estimates indicate that approximately 20% of VSCC are associated 
with HPV. 9 However, data on the influence of HPV-status on the prognosis of 
patients with vulvar cancer is either lacking or conflicting. 
 
Two recent publications have reported that among women with VSCC the 
presence of HPV-DNA in tumour tissue is an independent prognostic factor 
associated with a favourable outcome.10, 11 Studies have also reported 
tumours expressing p16, a biomarker associated with HPV positivity12 are 
less likely to recur.10, 13 In contrast, Alonso et al investigated presence of HPV 
DNA with response to radiotherapy; in multivariable analysis only the 
presence of lymph nodes metastasis was associated with outcome.14  A 
similar finding was reported by another study15, that in the presence of lymph 
node metastasis, HPV status if the vulvar lesion was not predictive of 
outcome.  
 
Given the aforementioned knowledge gaps, the aim of the present study was 
to characterize VIN and VSCC in a population-based series of patients with 
respect to (1) progression of VIN to VSCC (2) type-specific HPV prevalence 
and (3) influence of HPV status on clinical outcome/prognosis in VSCC.  
Scotland Is an ideal location for a study of a relative rare cancer such as 
VSCC due to the almost complete population uptake of health care through 
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the National Health Service 16 and consistent national coverage of collection 
of health service data.17 
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Materials and Methods 
 
Case selection and identification  
All cases of VIN and VSCC diagnosed between 01/01/2001 and 31/12/2014 
were identified using the National Health Service, Greater Glasgow and Clyde 
pathology database, a prospectively gathered record of all routine pathology 
reports that links to a bio-repository archive of all processed tissue. The 
Health Board covers the following locations: West Dunbartonshire; East 
Dunbartonshire; East Renfrewshire; Glasgow City; Inverclyde and 
Renfrewshire and covers a population of approximately 1.1 million people with 
about 50% of these being women.18 Health services in Scotland are financed 
almost entirely out of general taxation and available to all inhabitants, with 
only a very small independent health care sector.16 VIN lesions were graded 
as part of routine National Health Service management as not otherwise 
specified (NOS), ‘low grade’ (LSIL/VIN1) or ‘high grade’ (HSIL/VIN2 or 3) 
dysplasia. Women often had multiple biopsies taken of a disease episode 
over a short time period and so the study population was divided into the 
following four groups to reduce misclassification of concurrent diagnosis as 
sequential disease: 1. All VIN lesions identified within 365 days of each other 
were treated as a single episode of VIN; 2. VIN recurrence was defined as 
two positive biopsies separated by 365 days or more; 3. VSCC defined as an 
incident case of cancer diagnosed within the study period; and 4. VIN 
progressing to VSCC, where 365 days or more separated the diagnoses of 
VIN and VSCC.  
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Identification, retrieval and review of cases 
To allow pathology review and HPV genotyping, tissue was retrieved from the 
National Health Service, Greater Glasgow and Clyde pathology biobank for 
cases of VIN and non-metastatic VSCC diagnosed between 01/01/2008 and 
31/12/2009. Detailed pathology review including classifying cases using the 
2015 International Society for the Study of vulvovaginal disease (ISSVD) 
terminology of vulvar squamous intraepithelial lesions into low-grade 
squamous intraepithelial lesion (LSIL) and high-grade SIL (HSIL) and 
differentiated vulvar intraepithelial neoplasia (dVIN). To enable analysis of VIN 
recurrence or VSCC progression and associated pathological and viral factors 
in this cohort, any samples taken between 01/01/2001 and 31/12/2014 from 
these women were also reviewed and sent for HPV genotyping.  All retrieved 
tissue underwent pathology review by two consultant pathologists.  
 
VIN and VSCC case management 
For the duration of this study patients were managed within the National 
Health Service, Greater Glasgow and Clyde, tertiary gynaecology oncology 
referral centre, which offered dedicated vulval clinics for patients with VIN and 
VSCC.  For VIN and VSCC cases the treatment philosophy was based on 
surgery during this time frame, aiming for a 1cm margin based on clinical 
findings at the time of surgery.  Where positive margins were identified after 
the primary excision then re-excision would be considered to achieve clear 
margins. However, this decision would be taken on an individual case basis. 
All patients were followed up in the tertiary gynaecology oncology referral 
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centre at least twice per year with a physical examination and radiological 
procedure in cases of VSCC.  
 
HPV genotyping 
Formalin fixed, paraffin-embedded blocks were selected and a 10 μm section 
obtained for subsequent nucleic acid (NA) extraction and HPV genotyping. NA 
extraction was performed.19 Subsequently, HPV genotyping was performed 
using the Optiplex HPV Genotyping assay (Diamex, Heidelberg, Germany). 
This assay detects 24 HPV types including all established oncogenic or high 
risk (HR)-types and, as a check for specimen adequacy, incorporates a 
cellular housekeeping control (beta globin). Immunohistochemical staining for 
p16 was carried out using BD Pharmingen p16 (Cat No51-1325GR). Cases 
were coded negative if staining was negative or focal and positive if staining 
diffuse.                                                                                                                                                                                                            
 
Annotation of cases with clinical information  
The demographic and clinical data/variables collected were age, FIGO cancer 
stage,20 treatment modality, immunosuppression, smoking status, date and 
cause of death and Scottish Index of Multiple Deprivation (SIMD) quintiles 
which identifies small area concentrations of multiple deprivation.21  Date of 
diagnosis was taken as date of pathology sample collection.  
 
Analysis 
Analysis of factors associated with HR-HPV infection was carried out in 
Stata12 (StataCorp LP, College Station, TX). Kappa scores for agreement 
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between HR-HPV genotype status and p16 positivity were calculated. 
Associations between HPV-status and clinical variables were estimated using 
the Pearson chi-squared test. Both unadjusted and adjusted odds ratios 
(ORs) for HPV positivity and 95% confidence intervals (CIs) were calculated 
using logistic regression modeling. For women with VIN, rates of recurrent or 
progressive disease by HPV status and co-factors were estimated accounting 
for differing person years of contribution for each individual.  The univariate 
association between recurrent and progressive disease and each of the 
clinical variables were assessed using Cox proportional-hazards models. 
 
In those with VSCC, rates of overall survival and progression-free survival 
were estimated by means of the Kaplan–Meier method and Cox proportional-
hazards models were used to estimate unadjusted hazard ratios for all of the 
clinical variables. A fully adjusted model was created using all variables and 
then backwards selection used to remove insignificant variables at each stage 
resulting in final adjusted hazard ratios to estimate the difference in survival 
by HR HPV- status. All Cox proportional-hazards models were run using R 
version 3.2.3. 
 
All P-values were 2-sided and we considered P <0.05 to be statistically 
significant. 
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Governance 
Permission was gained from National Health Service Greater Glasgow and 
Clyde (Biorepository Reference Number 96). 
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Results 
 
Prevalence of VIN and VSCC between 2001-2014 and association with 
age at diagnosis 
There were 6666 pathology specimens of benign and malignant vulvar tissue 
and of these, there were 949 individual women with either VIN or VSCC 
identified. Incident cases during the selected time period of VSCC accounted 
for 43% (404/949) of samples and VIN, 57% (545/949).  Table 1 describes the 
cases pathological categories and age. The median age of diagnosis of VSCC 
decreased from 76 years (IQR 64-89) in 2001 to 64 years (IQR 50-78) in 2014. 
The median age at VSCC diagnosis was significantly older compared to 
women presenting with a diagnosis of pre-invasive disease (65 Vs 47 years 
[p<0.001]).  
 
Underlying pathology of VIN and VSCC and rates of progression 
between 2001-2014 
In this cohort for samples collected between 2001 and 2014, the prevalence 
of recurrent VIN and VIN progressing to VSCC was 18% (96/545) and 6% 
(32/545), respectively.  The median time that women had recorded episodes 
of recurrent VIN (with no documented pathology of VSCC) was 3.1 years 
(range 1.7-14.3 years). The median time from first recorded VIN to VSCC was 
2.8 years (range 1.1 to 9.1 years). When using the pathology scores recorded 
for National Health Service management, no association was found between 
grade of lesion (low grade versus high grade) and risk of VIN recurrence 
(p=0.9) or progression to cancer (p=0.7).  
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VIN and VSCC pathology for detailed subset between 2008 and 2009 
A subset of the above cases diagnosed between 01/01/2008 and 31/12/2009 
were selected for HPV genotyping (Table 1). This time period was chosen on 
the basis complete case ascertainment of pathology specimens and to allow 
length of time of follow-up for survival analysis. Two cases were associated 
with immunosuppressive drug administration to prevent transplant rejection.  
 
The five-year overall survival for women less than 60 years, 60 years to 79 
years, and 80 years and older was 90%, 50% and 15% respectively.  Stage of 
cancer was also related to 5-year overall survival with FIGO Stage 1, 2 and 
3/4a having survival rates of 79%, 40% and 38% respectively.     
 
HPV type specific distribution in VIN  
For cases of VIN, valid results were obtained for 112/118 samples; two results 
were considered invalid when tests were negative for both HPV and beta 
globin, and four results were not available due to sampling/operational 
reasons.   HPV infection was identified in 87% cases (97/112) and HR-HPV 
types in 85% (95/112). Of cases where HPV was detected, single infections 
with 16, 18, 33, 42, 45 and 51 were identified in 79, 2, 6, 2, 1 and 1 cases 
respectively.  The occurrence of multiple infections of 16/18, 16/33, 16/33/53, 
16/42, 18/6 and 16/6/11 all occurred in a single case each.  The level of 
agreement between HR-HPV genotype and p16 staining was strong (79%, 
P=0.001). 
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In the adjusted multivariable analysis (Table 2) the odds of high-risk HPV-
positivity was higher in women with HSIL (p=0.04) compared to women with 
LSIL or dVIN. Women with VIN staining positive for the biomarker p16 were 
also more likely to have pre-invasive disease associated with HR-HPV 
(p=0.04).  
 
 
Type specific persistence of HPV in women with recurrent VIN  
A total of 34/36 cases of VIN diagnosed between 01/01/2008 and 31/12/2009 
met study criteria for recurrent VIN and had valid HPV results. The HR-HPV 
was detected in 88% (30/34) of the first recorded samples and type specific 
infections were HPV 16 alone in 25/34 cases and 16/18, 16/33/53, 16/6/11, 33 
and 51 in one case each. Additional samples from these 34 cases, also 
separated by at least one year, were sought from the larger (01/01/2001 and 
31/12/2014) database. There were 65 such samples identified, with each 
woman having between 3 and 8 samples. The prevalence of HR-HPV 
positivity in the first biopsy sample for each case of recurrent VIN did not differ 
significantly from women with a single episode of VIN (88% [30/34] Vs 89% 
[58/65], p=0.7). Of the 34 recurrent VIN cases, the detection of HR-HPV was 
retained and did not change HPV sub-type in 28 cases, never detected in 3 
cases, lost from 2 cases and gained HPV in one. All gained and lost HPV 
types were 16. 
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Type specific persistence of HPV in women with progressive VIN  
There were 13/14 women identified between 01/01/2008 and 31/12/2009 that 
met study criteria for VIN progressing to VSCC and had valid HPV results at 
baseline. As above, additional samples for these women were also extracted 
from the larger (01/01/2001 and 31/12/2014) database.  Cases progressing 
from VIN to VSCC had between 1 and 9 biopsies (median=4) prior to a 
diagnosis of invasive cancer. The presence of HR-HPV in the baseline 
sample was less common in VIN from women whose disease progressed to 
VSCC compared to VIN that did not transform to cancer (89% [88/99] Vs 54% 
[7/13], p<0.001).  Among VIN cases that progressed to VSCC all HPV-
positive cases (n=7) at baseline were associated with type 16 HPV alone.  
Two HPV 16 positive cases progressed to a HPV negative tumour. Nine of the 
fourteen cases had high-grade dysplasia reported at other perineal 
anatomical sites. 
 
Rates if recurrence and progression of VIN 
We next investigated the rate of recurrence VIN or VIN progressing to cancer 
by HR-HPV status and other clinical variables (Table 3).  VIN associated with 
HR-HPV had a lower rate of progression to cancer (HR 0.02, p=0.001). In 
addition, HSIL lesions compared to dVIN disease were less likely to progress 
to invasive disease (HR 0.17, p=0.003). There was also evidence that women 
older than 70 years of age had a higher rate of disease progressing to cancer 
(age 70-79 year HR 4.46, p=0.01 and women 80 years and over HR 20.92, 
p=0.001).  Women with dVIN tended to be older than woman with HSIL or 
LSIL (Table 1) and were less likely to be associated with HR-HPV (Table 2).  
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HPV type specific distribution in VSCC 
Of the 66 cases of VSCC, valid HPV results were obtained from 62/66; three 
were classed invalid by testing both HPV negative and negative for beta 
globin and 1 was not available for operational reasons.  HPV infection was 
present in 52% cases (32/62) and all types identified were high-risk. HPV 16 
was identified in 30 cases and type 31 and 33 in one case each. Only one 
case had dual HPV types; 16 and 42. There was almost perfect agreement 
between HR-HPV genotype and P16 positivity (82%, P<0.001). In the 
adjusted multivariable analysis (Table 4) the presence of VIN surrounding a 
tumour remained an independent predictor of HR-HPV positivity (p=0.003), as 
did positive staining for p16  (p=0.006). 
 
Influence of HPV status on survival in patients with VSCC 
The mean follow-up time from incident diagnosis was 5.8 years (range 55 
days to 14 years). The 5-year rates of OS were 78% in the HR-HPV-positive 
group and 49% in the HPV-negative group. The 5-year rates of progression 
free survival (PFS) were 87% in the HR-HPV positive group and 47% in the 
negative group. Rates of overall survival and progression-free survival 
estimated by means of the Kaplan–Meier method are shown in Figure 1 and 
Figure 2 respectively.  
 
In the unadjusted analysis, women with HR-HPV positive VSCC had better 
over-all survival (p=0.005, and progression-free survival (p=0.001)  (Tables 5 
and 6). After adjustment for age and cancer stage, patients with HPV-positive 
tumours had a 51% reduction in risk of death but the association was not 
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statistically significant ((hazard ratio, 0.43, p=0.09) (Table 6). However, there 
was a statistically significant 70% reduction in risk of disease progression 
(hazard ratio, 0.32, p=0.02) compared to those with HPV negative tumours 
(Table 5).  
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Discussion 
 
We have conducted a detailed population-based study to examine rates of 
progression of VIN to VSCC and influence of clinical factors. Moreover, we 
have determined type-specific HPV prevalence in vulvar disease and the 
influence of HPV status on clinical outcome in VSCC. Our data reveal key 
novel aspects of VIN and VSCC. In particular, the age at which women are 
diagnosed with VSCC is falling and there is a significant time gap between 
first diagnosis of VIN and progression to invasive disease. HR-HPV infection 
was very common in VIN and present in just over 50% of VSCC. Most 
importantly, detection of HR-HPV was associated with a reduction in risk of 
progression from VIN to cancer and associated with improved progression-
free survival of VSCC. 
 
We have reported that the incidence of vulvar cancer in Scotland has 
increased by about 64% in the past three decades, particularly among young 
women.2, 3  The above data indicate that the epidemiology of vulvar disease 
may be changing – with the diagnosis of VSCC occurring at an earlier age 
according to this series. These findings are consistent with previous work in 
Scotland which showed that the European age-standardised ratio for VSCC 
between 1972–1976 and 2007–2011, increased from 3.3 per 100,000 to 4.2 
per 100,000 and that this increase was most prominent among younger 
women.3 These data also reconcile with the US study, which assessed VSCC 
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data from nine US Cancer registries for the period 1973-2004 and showed 
that VIN and VSCC increased 3.5% and 1.0% respectively, each year with the 
increase observed in all categories but the largest increase occurred in 
women aged 54 or less.22  
 
Reasons for this phenomenon are unclear at present. It is feasible that 
changed clinical practices for the ascertainment and management of vulval 
disease may be influential in the case of VIN, but we do not believe this would 
be the case for VSCC as cancer related symptoms and access to care have 
not appreciably changed between 2000 and 2014 in Scotland. Changed 
sexual behaviour(s), including age at first intercourse, which in turn facilitates 
transmission of HR-HPV could result in increased incidence of disease. 
Evidence of a secular increase in HR-HPV prevalence has been reported 
elsewhere23 and the significant increase in HPV-associated oropharyngeal 
cancer over the last two decades may be due to an epidemic of highly 
transmissible HR-HPV.24  In addition, increased incidence of HR-HPV-positive 
oropharyngeal cancer has been partly attributed to changed sexual 
practices.25  Sexual behaviours associated with risk for vulval infection are 
considered similar to those for cervical infection and include age, single 
versus in partnership, age at first intercourse and number of sexual partners. 
26 However, given that we did not specifically quantify or account for sexual 
behaviours in this study we are not able to address this directly and in fact 
there are few analyses on sexual behaviours and practices in women with VIN 
and VSCC – particularly when compared to those undertaken in those with 
cervical or increasingly, head and neck cancer. In terms of risk of HPV 
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acquisition and tobacco use,  smoking prevalence in Scotland remains higher 
than both England and Wales, there has been a downward trend from the 
mid-1970’s to the present time. 27 
 
Clearly, it is of interest to promptly identify which women exhibit a greater 
chance of recurrence, which has a prevalence of about one-fifth of cases in 
this study.  The pathological grading of VIN as defined by National Health 
Service local practice, showed no association with recurrence and this may 
support the concept there is not a continuum with VIN lesions leading to 
cancer as demonstrated for CIN and cervical cancer.28  Using the ISSVD 
terminology, cases of dVIN were more likely to recur or progress compared to 
LSIL and HSIL, but numbers were small.  While no other clinical factor studied 
identified risk of progression or recurrence of VIN, identifying the small 
number of women with dVIN, who tend to be older and HR-HPV negative for 
close active monitoring may be important.  
 
Another crucially important group to identify are those who have VIN that will 
progress to VSCC. In our series, the number of VIN cases that progressed to 
VSCC was between 6% and 10%. This figure is similar to that described in a 
recent analysis of 1094 Dutch women with VIN where the cumulative 20 year 
incidence was 8.9%.29 VIN associated with HR-HPV and categorised as HSIL 
had a lower rate of progression to cancer.  Younger women also appeared 
less likely to progress compared to women in older age groups. The results 
presented here suggest that VIN regression rates in HR-HPV associated high-
grade disease may be high.  This is important to characterised to prevent 
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young women having extensive morbid surgical management of pre-invasive 
disease, which may regress. Low-grade cervical disease is characterised by 
transient infection while high-grade disease is due to subsequent persistent 
HPV infection.  Our data suggest that in many cases, VIN progression to 
VSCC may not follow this pathway. Our data was limited due to small 
numbers and use of a retrospective cases series. A study using a much larger 
patient group will be necessary in future to extend and clarify these findings.  
 
The development of VSCC after VIN treatment is relatively high compared to 
progression after treatment of CIN. 30  This may be due to widespread field 
change over the perineal area; in the group that underwent HPV testing nine 
of the 14 cases that progressed had severe dysplasia at another 
perineal/genital site. In addition, technically it is more challenging to treat 
vulvar disease compared to cervical disease.  Unfortunately, unlike cervical 
disease, there is no equitable screening and recall system for VIN. Our study 
indicates that development of such a system would be advantageous because 
of the significant length of time taken for progression from VIN to VSCC and 
the opportunity for an intervention to prevent VSCC. Cellular biomarkers 
which have been interrogated in the vulvar context have included chemokine 
receptor proteins 31, p16 and p53 10 and ROCK1 protein.32  Charting the loss 
or gain of viral biomarkers 33 may shed significant light on the unusual 
aetiology of VIN and progression to VSCC. 
 
With respect to HPV status, HPV infection was identified in 87% of VIN cases 
with HPV type 16 and/or 18 present in 78% of these.  Comparatively, HPV 
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was detected in 52% of VSCC cases with HPV 16 identified in 48% of cases. 
VSCC surrounded by VIN was much more likely to be HR-HPV positive and 
may represent widespread perineal/genital HPV infection and field change 
caused by the virus. There is a paucity of contemporary data in the UK on 
type-specific prevalence of HPV in vulval disease. The limitation of this and 
other studies is that vulvar disease is relatively rare. Consequently, these data 
are important to help inform the potential impact of the prophylactic HPV 
vaccines on vulval disease, particularly as vaccine uptake rates in the UK 
have been consistently high (>90%) since introduction in 2008.34 HPV status 
was significantly associated with age in our study.  Our data indicates that the 
prophylactic HPV vaccine will prevent about half the cases of VSCC under the 
age of 69 years. It should be noted that a number of cases of VIN were 
associated with HPV 33, which would be prevented by immunisation with 
bivalent vaccine through cross-protection but would not be prevented by the 
quadrivalent vaccine currently used as part of the national programme.35 
 
One key finding of this study was that women who had HPV-positive VSCC 
had a significantly improved prognosis compared to those who had HPV 
negative tumours, and that this observation was maintained after adjustment 
for age at diagnosis and tumour stage. This observation reconciles with the 
recent study of Hay et al (2016) who assessed the impact of HPV status 
(through HPV specific PCR and p16 staining) and p53 mutation status in 
series of 92 VSCC diagnosed between 1998-2007.10 Notably HPV positive 
(and p16 positive) patients were less likely to have recurrence and there were 
no VSCC related deaths whereas p53-mutatant positive patients had a 
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greater probability of recurrence and were significantly more likely to die from 
VSCC. While we did not measure p53 status in the present study – the 
observation that HPV status confers a favourable outcome is consistent.    It is 
now well established that HPV positive OPSCC is associated with improved 
clinical outcomes and annotation of OPSCC for HPV status to provide 
clinicians with insight into a patients’ prognosis is becoming more widespread. 
7 Furthermore, although the relative proportions are small – cervical cancers 
where no HR-HPV is detected have been shown to have a worse outcome. 8  
The drivers as to why HPV associated neoplasms are associated with 
improved outcomes compared to their HPV negative counterparts are not fully 
established and are complicated by influential confounders, particularly 
smoking which is often challenging to document accurately.  However the 
higher levels of host-mutation associated with non HR-HPV cancers may 
explain the differential outcome at least in part.   
 
To conclude, the management of VIN remains a challenge. While HPV 
immunisation will significantly impact on this disease, the benefits realisation 
will take time and will not protect against all cases – including HPV-negative 
cases of VSCC, which appear to have a worse prognosis. HPV testing should 
be considered routine for VSCC management, to guide prognosis and to drive 
development of novel approaches in treatment. While much has been 
invested in the development of biomarkers for the improved management of 
pre-invasive cervical disease there is a comparative lack of studies in the VIN 
context – more are needed to inform and support the improved management 
of this complex, disease which appears to be increasing in incidence.  
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